VolitionRX (VNRX) News
NYSE: VNRXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
0.1621-0.0026 (-1.58%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VNRX news summary
We found 4 recent headlines mentioning VolitionRX (VNRX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq. For price context, VNRX is down 1.58% at $0.1621. The most recent story, "VolitionRx (VNRX) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest VolitionRX headlines
- VolitionRx (VNRX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business UpdateVolitionRx Limited reported its financial results for the third quarter of 2026, with revenue increasing 157% to approximately $1.6 million compared to $0.6 million in the third quarter of 2025,…Nasdaq
- VolitionRx Limited CEO Cameron Reynolds Agrees to Further Temporary Salary Reduction to $236,970.50On November 10, 2026, Singapore Volition Pte. Limited, a wholly-owned subsidiary of VolitionRx Limited, and Mr. Cameron Reynolds, Chief Executive Officer and President of the Company, entered into an…Nasdaq
- VolitionRx Limited Announces $500,000 Partial Prepayment of Convertible NoteVolitionRx Limited entered into a waiver and consent on October 23, 2026, with Lind Global Asset Management XII LLC regarding a senior secured convertible promissory note issued January 15, 2026, in…NasdaqVNRX, BF.A